EXHIBIT 81

From: Feniger, Angela

Sent: Tuesday, March 22, 2016 8:36 AM **To:** Jones, Heather; 'Zach T Hall'

Cc: Dec, John; Wydro, Phillip; Brantley, Eric; Macrides, Stephen; Poshni, Faiza; Shukla,

Jaydeep; Karaban, Dino

Subject: RE: EXTERNAL: Cedegim for all Par Orders - SOM

Thank you Heather for looping into the conversation regarding SOM.

John/Heather,

Please include myself and my staff so that we are on the same page regarding the SOM project moving forward. We need to be up to speed on this matter in order to address any questions upon a DEA inspection at the NY Sites as to our process for monitoring/manage/addressing SOM (orders of interest).

Thank you.

Angela Feniger, MBA | Director, DEA Compliance & QA Documentation

Par Pharmaceutical Companies, Inc. | 2 Ram Ridge Road | Spring Valley, NY 10977

Phone: angela.feniger@parpharm.com

www.parpharm.com

From: Jones, Heather [mailto:Heather.Jones@parpharm.com]

Sent: Monday, March 21, 2016 7:02 PM

To: Zach T Hall

Cc: Dec, John; Feniger, Angela; Wydro, Phillip; Brantley, Eric; Macrides, Stephen

Subject: RE: EXTERNAL: Cedegim for all Par Orders

Dear Zach,

My apologies for the late response, but I was out on PTO last week with only iPhone access to email.

I had my first meeting with John Dec on March 3, 2016 about JDE questions unrelated to SOMs / Cegedim.



Case: 1:17-md-02804-DAP Doc #: 2181-87 Filed: 08/12/19 3 of 5. PageID #: 325993



Please let me know if you would like to meet or have any questions or concerns.

Thank you.

Please note a change of e-mail address below, effective January 28, 2016. Thank you.

Best Regards,

Heather S. Jones Director DEA Compliance

Par Pharmaceutical 130 Vintage Drive Huntsville, AL 35811

<u>Direct:</u> Mobile:

Heather.Jones@parpharm.com



This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual(s) or entity(ies) named in the e-mail address. If you are not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please notify the sender immediately so that the Par can arrange for proper delivery, and then please delete the message from your system. Thank you.

From: Zach T Hall [mailto:Zach.Hall@ey.com]
Sent: Monday, March 14, 2016 12:43 PM

To: Jones, Heather

Case: 1:17-md-02804-DAP Doc #: 2181-87 Filed: 08/12/19 4 of 5. PageID #: 325994

Cc: Dec, John

Subject: EXTERNAL: Cedegim for all Par Orders

Good Afternoon Heather Jones,

My name is Zach Hall and I'm supporting change management for the One Face to the Customer project (OFTC/JDE Implementation Phase 1).

I understand that you lead DEA Compliance at Par South and that Par South will take on Cegedim for all Par orders. From a change management perspective, it's important that the DEA Compliance team at Par North is also aligned and that everyone understands what their role(s) is when Cegedim is deployed. What discussions with the Par North DEA Compliance team about Cegedim have taken place? If additional alignment is needed, I would be glad to help set-up a discussion with you and the Par North team.

Thank you.

Regards,

Zach Hall



Zachary T. Hall | People Advisory Services | Manager

Ernst & Young LLP 8484 Westpark Drive, McLean, VA 22102, United States of America Mobile: +1 216 543 6215 | zach.hall@ey.com

Website: http://www.ey.com

Any tax advice in this e-mail should be considered in the context of the tax services we are providing to you. Preliminary tax advice should not be relied upon and may be insufficient for penalty protection.

The information contained in this message may be privileged and confidential and protected from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by replying to the message and deleting it from your computer.

Notice required by law: This e-mail may constitute an advertisement or solicitation under U.S. law, if its primary purpose is to advertise or promote a commercial product or service. You may choose not to receive advertising and promotional messages from Ernst & Young LLP (except for EY Client Portal and the ey.com website, which track e-mail preferences through a separate process) at this e-mail address by forwarding this message to no-more-mail@ey.com. If you do so, the sender of this message will be notified promptly. Our principal postal address is 5 Times Square, New York, NY 10036. Thank you. Ernst & Young LLP

This e-mail transmission, including any attachments, is intended only for the individual(s) or entity(ies) named in the e-mail address and may contain confidential or proprietary information that may be subject to protections afforded to certain types of confidential and/or proprietary information, including attorney-client privilege. If you have any reason to believe that you are not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby

Case: 1:17-md-02804-DAP Doc #: 2181-87 Filed: 08/12/19 5 of 5. PageID #: 325995

notified that any review, use, disclosure, copying, distribution, or reliance upon the contents of this e-mail transmission, and any attachments thereto, is strictly prohibited. If you have received this e-mail transmission in error, please notify the sender immediately, so that Endo can arrange for proper delivery, and then please permanently delete the original and any copy of this e-mail transmission from your system and any printout thereof. Thank you.